Corporate Retrospective 2007: Bruker
We are pleased indeed to have been partnering with LCGC for North America many years in briefing scientists worldwide about our numerous LC–MS product announcements and extensive LC–MS applications news.
We are pleased indeed to have been partnering with LCGC for North America many years in briefing scientists worldwide about our numerous LC–MS product announcements and extensive LC–MS applications news. We find LCGC application notes to be a great tool to inform scientists about the very latest technological advances. LCGC has a well-informed readership that understands the research implications of our novel new LC–MS capabilities. LCGC application notes are an excellent way for us to provide the scientific community with real world data. In addition, we find that our advertisements in LCGC are well received by scientists, often generating requests to visit our worldwide demonstration labs to test out our newest instruments with their most challenging real world samples.
We consider LCGC to be an ideal medium for communicating news on all our MS capabilities.
Two years ago, we introduced the world's first high-capacity ion trap with electron transfer dissociation (ETD) capability. Last year at Pittcon 2006, our newly announced post-translational modification methods further extended our customers' ability to achieve automated, intelligent phosphorylation, and glycosylation characterization. The announcement enabled this important branch of proteomics on our robust, ultra-high sensitivity ion traps, and further established Bruker Daltonics as the leader in PTM research, ETD, and proteomics research by mass spectrometry. LCGC application notes are our vehicle of choice for communicating this kind of scientific advance.
In combination with the exceptional performance of our mass spectrometers in acquisition speed, mass accuracy, speed, and conventional collision induced dissociation, Bruker's advanced ETD technology has been opening the door for many of our customers worldwide to easily access the type and location of various PTMs, both quickly and conveniently. Our customers are finding that ETD fragmentation of large peptides results in a very complete set of c-and z-fragments due to the random fragmentation of all N-Cα bonds. These customers are seeing that the Bruker ETD takes full advantage of the excellent mass accuracy of the ion trap, making it the ideal tool for de novo sequencing applications. We'll publish more application notes on these kinds of topics in all the European, North American, and Asia-Pacific LCGC editions on a regular basis.
Clive Seymour
Clive Seymour
Vice President for Asia-Pacific
Bruker Daltonics
Bremen, Germany
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
